Yikon Genomics
Minhang
About Yikon Genomics
Yikon Genomics is a leading solution-based single cell sequencing company. Currently based on the patented MALBAC® technology from Harvard University, Yikon provides complete solutions in the fields of reproductive health and cancer diagnostics with liquid tumor biopsy. The MALBAC-PGS™ and MALBAC-PGD™ solutions offer the most accurate and comprehensive embryo testing results for physicians to choose the best embryos with balanced chromosomal copy numbers,without inheriting the known disease-associated alleles. The MALBAC-PGS™ and MALBAC-PGD™ solutions have helped thousands of couples to achieve successful pregnancies. Yikon will continue to interpret the code of life and bring people the hope and joy of life.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 501 – 1,000
- Estimated revenue: $1K – $10K
- Total funding: $69.7M
- Funding stage: Late Stage Venture
- Last round: Series D (May 2021)
- Website: yikongenomics.com
- Phone: 0086-400-9123-918
Industries & Categories
Biotechnology, Genetics
Social Profiles
Canonical: https://fsome.com/organization/yikon-genomics-17954 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.